GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.16 USD
-0.01 (-3.04%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.16 0.00 (0.31%) 5:06 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 1 - 20 ( 161 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q24 Results; Strategic Review and Corporate Restructuring Plan Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Corporate Restructuring and Strategic Review Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Some Positive Subset Data From Phase 3 Trial of Uproleselan in r/r AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Phase 3 Trial of Uproleselan in r/r AML Misses Primary Endpoint of OS; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q23 Results; All Eyes on Phase 3 Trial of Uproleselan Before Upcoming Topline Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Positive Initial Results From Phase 1a Healthy Volunteer Study of GMI-1687
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Partner in China Completes Enrollment in Phase 3 Bridging Study of Uproleselan in r/r AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Independent Study Presentation at ASH Highlights New Positive Data for Uproleselan
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q23 Results; Phase 3 Data For Uproleselan in R/R AML Projected for 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
First Cohort of Healthy Volunteers Dosed in Phase 1a Study of GMI-1687
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q23 Results; Uproleselan Phase 3 Data Expected 2Q24; GMI-1687 to Enter the Clinic This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Addition of Time-Based Final Analysis Cleared by FDA For Phase 3 Trial of Uproleselan in r/r AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q23 Results; Final OS Events Trigger For Phase 3 Study of Uproleselan in AML on Track for 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q22 Results; Phase 3 Uproleselan Study Final Event Trigger Expected 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
IDMC Recommends Phase 3 Study of Uproleselan For r/r AML to Proceed to Planned Final Survival Analysis; Lower PT by $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q22 Results; Phase 3 Interim Data IDMC Review Expected by End of 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q22 Results; Waiting on Phase 3 Data For Uproleselan in r/r AML; Lower PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E